熱門資訊> 正文
吉利德行使大会生物科学疱疹项目许可证
2025-12-23 00:42
- Gilead Sciences (GILD) has exercised an option to license Assembly Biosciences (ASMB) herpes simplex virus helicase-primase inhibitor programs for recurrent genital herpes.
- The deal covers phase 1 oral candidates ABI-1179 and ABI-5366. Both inhibit the enzyme viral helicase-primase, which is necessary for herpes virus replication.
- The two companies signed an agreement in October 2023 for a 12-year partnership to research and develop novel antiviral therapies. Assembly received an $84.8M upfront payment and a $15.2M equity investment from Gilead, which also agreed to buy ~30% of Assembly Bio stock. In addition, Assembly is eligible for ~$330M in milestone payments per program.
More on Gilead Sciences
- Gilead Sciences, Inc. (GILD) Presents at Evercore 8th Annual Healthcare Conference Transcript
- Gilead Sciences, Inc. (GILD) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
- Gilead Sciences: About To Break Out
- Bristol Myers, Merck, Amgen among latest to announce U.S. drug pricing deal
- More pharmas expected to sign drug pricing deals with Trump on Friday - report
推薦文章
華盛早報 | 炮轟鮑威爾！特朗普稱未來數周公佈美聯儲人選；英偉達突發！美國放寬對H200芯片出口中國管制
美股機會日報 | 全球央行行長聯合聲援鮑威爾！CPI數據將襲，美聯儲春季降息要涼？
打新攻略 | 11只上市新股「0」破發！2026年人均「大肉籤」，還有哪些新股即將來襲？
1月財報預告 | 美股Q4財報季拉開帷幕！高盛、臺積電打頭陣，誰將交出超預期財報？
花旗：料AI雲服務需求仍強勁 互聯網板塊首選騰訊控股
華盛早報 | 中國資產爆發！阿里巴巴大漲超10%；谷歌市值突破4萬億美元！官宣與蘋果合作
美股機會日報 | 預期突變！摩根大通預計美聯儲2026年不降息；黃金白銀創新高，礦業股盤前齊飆升！
華盛早報 | 黃金、白銀狂飆！特朗普「威脅」引地緣政治風險升溫；商業航天爆發！中國新增20萬顆衞星申請
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
